3H-Spiro[furo[3,4-c]pyridine-1,4'-piperidine] | 475437-27-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3H-Spiro[furo[3,4-c]pyridine-1,4'-piperidine]
• 英文别名: spiro[3H-furo[3,4-c]pyridine-1,4'-piperidine]
• CAS: 475437-27-5
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.24
• InChiKey: PSPZNNARAQMDDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted Spiro-amide Compounds
  申请人：Schunk Stefan

  公开号：US20100249095A1

  公开（公告）日：2010-09-30

  Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  将与式I相对应的螺环酰胺化合物替代为R5至R8、D、X、Y和Z具有定义含义的过程，用于制备这种螺环酰胺化合物，含有这种化合物的药物组合物，以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• AZASPIRO DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20080161332A1

  公开（公告）日：2008-07-03

  The present invention is concerned with novel indol-3-yl-carbonyl-azaspiropiperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of the general formula (I) wherein R 1 to R 6 , U, V, W, X, Y and Z are as defined in the specification.

  本发明涉及新型吲哚-3-基-羰基-氮杂螺环哌啶衍生物作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们用于治疗焦虑和抑郁症等疾病的用途。具体而言，本发明涉及一般式(I)的化合物，其中R1至R6、U、V、W、X、Y和Z如规范中定义。
• Diaryl ketimine derivative
  申请人：Ando Makoto

  公开号：US20090247560A1

  公开（公告）日：2009-10-01

  Provided is a compound of a formula (I): [wherein R 1a and R 1b are the same or different, representing a hydrogen atom, etc.; R 2a and R 2b are the same or different, representing a hydrogen atom, etc., or R 2a and R 2b , taken together, form —CH 2 CH 2 —, R 3a and R 3b are the same or different, representing a hydrogen atom, etc.; or R 3a and R 3b , taken together, form —CH 2 CH 2 -etc.; Y 1 and Y 2 represent —C(R) 2 —, etc.; Z represents OR, NR 2 , etc.; R represents a hydrogen atom, a C 1-6 alkyl group, etc.; Ar 1 represents a 6-membered aromatic carbocyclic group, etc.; Ar 2 represents a 6-membered aromatic carbocyclic group, etc; A 3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  提供的是化合物公式(I)的复合物：[其中R1a和R1b相同或不同，代表氢原子等；R2a和R2b相同或不同，代表氢原子等，或者R2a和R2b结合形成-CH2CH2-，R3a和R3b相同或不同，代表氢原子等；或者R3a和R3b结合形成-CH2CH2-等；Y1和Y2代表-C(R)2-等；Z代表OR、NR2等；R代表氢原子、C1-6烷基等；Ar1代表6-成员芳香环烷基等；Ar2代表6-成员芳香环烷基等；A3代表6-成员芳香环烷基等。]该化合物可用作治疗中枢障碍、心血管障碍、代谢障碍的药物。
• Substituted Spiro-Amide Compounds
  申请人：Gruenenthal GmbH

  公开号：US20130231327A1

  公开（公告）日：2013-09-05

  Substituted spiro-amide compounds corresponding to formula I in which R 5 through R 8 , D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  本发明提供了对应于式I的取代螺环酰胺化合物，其中R5至R8、D、X、Y和Z具有定义的含义，制备这种螺环酰胺化合物的过程，含有这种化合物的药物组合物以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• DIARYL KETIMINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2072519A1

  公开（公告）日：2009-06-24

  Provided is a compound of a formula (I): [wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form -CH2CH2-, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a and R3b, taken together, form - CH2CH2-etc.; Y1 and Y2 represent -C(R)2-, etc.; Z represents OR, NR2, etc.; R represents a hydrogen atom, a C1-6 alkyl group, etc.; Ar1 represents a 6-membered aromatic carbocyclic group, etc.; Ar2 represents a 6-membered aromatic carbocyclic group, etc; A3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  本文提供了一种式 (I) 的化合物： [其中 R1a 和 R1b 相同或不同，代表氢原子等；R2a 和 R2b 相同或不同，代表氢原子等、或 R2a 和 R2b 相同或不同，代表氢原子等；或 R3a 和 R3b 相同或不同，代表-CH2CH2-等； Y1 和 Y2 代表-C(R)2-等； Z 代表 OR、NR2 等。R 代表氢原子、C1-6 烷基等；Ar1 代表 6 元芳香碳环基团等；Ar2 代表 6 元芳香碳环基团等；A3 代表 6 元芳香碳环基团等]。该化合物可作为治疗中枢性疾病、心血管疾病和代谢紊乱的药物。